Products
Almirall launches Parapres Plus 32® and Parapres Plus Forte® to treat hypertension
-
In Spain only 4 out of every 10 hypertensive patients treated have their arterial hypertension (AH) controlled.
-
AH is one of the main cardiovascular risk factors. It has a prevalence of around 35% in people over 18 which rises to 68% in those over 60.
-
The aim of AH treatment is to reduce cardiovascular morbimortality associated with high blood pressure. Patients suffering from cardiovascular disease or diabetes should aim for an even greater reduction.
Barcelona, 1 December 2009.- Almirall, the international pharmaceutical company based in Spain, announces the launch of two line extensions Parapres Plus® (candesartan cilexetile/hydrochlorotiazide). Parapres Plus 32® and Parapres Plus Forte®are indicated to treat hypertensive patients whose blood pressure is not sufficiently controlled with monotherapy1.
AH is one of the main cardiovascular risk factors. It has a prevalence of around 35% in people over 18 which rises to 68% in those over 602.
Treatment of AH aims to reduce cardiovascular morbimortality associated with HBP. The general recommendation is to reduce HBP to below 140/90 mmHg. For patients with cardiovascular disease, diabetes or nephropathy it is reasonable to reduce HBP to figures below 130/80 mmHg3.
Parapres Plus 32® and Parapres Plus Forte® therefore aim to achieve greater blood pressure (HBP)4 control bearing in mind that in Spain it is only controlled in 4 out of every 10 hypertensive patients5.
About arterial hypertension
The WHO defines AH as a disorder with an often unknown pathogeny and which can end up causing an increase of diastolic and systolic pressure, as well as alternations of the vascular bed and functional alternations of the affected tissues.
Most patients do not have symptoms. This does not mean that it is not dangerous, as a large number of deaths occurring every year result from hypertension or complications to the cardiovascular system or kidney.
About Parapres Plus 32® and Parapres Plus Forte®
Parapres Plus 32® (Candesartan 32 mg + Hydrochlorothiazide 12.5 mg) and Parapres Plus Forte® (Candesartan 32 mg + Hydrochlorothiazide 25 mg) are specialities that reinforce the Parapres family of products, used to treat hypertensive patients.
These new presentations are indicated to control blood pressure in hypertensive patients who do not sufficiently achieve the target with monotherapy1.
With an excellent safety and tolerability4 profile these combinations contain candesartan cylexetile, whose high organic protection has been widely supported by the numerous studies performed on patients with cardiac insufficiency, kidney damage, ictus, etc…6
Parapres Plus 32® and Parapres Plus Forte® are administered just once a day1, which means better treatment compliance by patients7.
Almirall
Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, Spain, Almirall researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing.
The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and other dermatology indications.
Almirall is currently present in over 70 countries with direct presence in Europe and Latin America through 11 affiliates.
For further information please visit the website at: www.almirall.com
More information:
Ketchum/SEIS
Sonia San Segundo/Patricia Mansilla
Tel.: + 34 91 788 32 00
Bibliography
1 SmPc Parapres Plus 32 and Parapres Plus Forte
2 Banegas JR, Rodríguez-Artalejo F, De la Cruz Troca JJ, Guayar-Castillon P, Del Rey Calero J. Blood Pressure in Spain distribution, awareness, control and benefits of a reduction in average pressure. Hypertension.
3 2007 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. J Hypertension 2007;25:1105-1187
4 Bönner G et al. Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg Blood pressure. 2008;17(Suppl 2): 22-30
5 Llisterri et al. Control de la presión arterial en la población hipertensa española atendida en atención primaria. Estudio PRESCAP 2006. Med Clin (Barc). 2008;130(18):681-7
6 Meredith PA. Candesartan cilexetil – a review of effects on cardiovascular complications in hypertension and chronic heart failureCurr Med Res Opin 2007; 23(7): 1693-1705
7 Wetzels GE et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: A systematic review. J Hipertens 2004;22(10):1849-55
Press release